Trinity Biotech plc

NASDAQ:TRIB

Medical - Diagnostics & Research

Healthcare
$5.83 -5.73%

-$0.51 today

Market cap
$117.96M
Beta
1.00
P/E (TTM)
-0.1
EPS (TTM)
-$60.27
52W Low $8.00High $103.20

Volume 0.00M

Average 1.34M

TRIB Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Trinity Biotech plcNASDAQ: TRIB

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization growth accelerates

Q4 FY2025 depreciation & amortization of $728.46K rose 71.8% year over year, ahead of the +44.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.9% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Depreciation & amortization amounted to 6.1% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +71.8% holds above the trailing-twelve-month pace of +44.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$728.46K+10.9% QoQ
Last fiscal yearDec 2025
$2.68M+43.9% YoY
LTMDec 2025
$2.69M+44.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+71.8%——
1 year+43.9%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
2.68M USD
Year-over-year change
+43.9%
4-year CAGR
-0.6%

Depreciation & Amortization vs competitors

How TRIB compares with its peers on the latest reported figures

No competitor Depreciation & Amortization figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.15M62.52M56.83M61.56M43.79M
Cost of Revenue54.89M52.73M37.38M40.11M26.9M
Gross Profit33.45M22.05M19.45M21.44M16.89M
Gross Margin41.2%35.3%34.2%34.8%38.6%
Research & Development4.5M4.14M4.38M4.54M3.63M
Selling, General & Admin24.68M29.17M31.15M28.82M24.67M
Operating Expenses29.52M32.96M46.5M42.61M28.3M
Depreciation & Amortization2.74M2.33M1.78M1.87M2.68M
EBITDA10.59M(16.71M)(24.1M)(16.91M)(21.38M)
EBITDA Margin13.1%-26.7%-42.4%-27.5%-48.8%
Operating Income3.94M(15.27M)(27.05M)(21.17M)(11.42M)
Operating Margin4.9%-24.4%-47.6%-34.4%-26.1%
Interest Income1.22M303K1.17M0221K
Interest Expense7.1M24.73M10.15M9.57M13.11M
Other Income / Expenses(5.86M)(24.43M)(9.88M)(9.57M)(25.76M)
Income Before Tax(1.92M)(43.78M)(36.93M)(30.73M)(37.18M)
Pre-Tax Margin-2.4%-70.0%-65.0%-49.9%-84.9%
Income Tax Expense(74K)(194K)(59K)486K199K
Net Income875K(41M)(24.02M)(31.79M)(37.38M)
Net Margin1.1%-65.6%-42.3%-51.6%-85.4%
EPS (Basic)6.30(180.00)(96.00)(52.98)(60.00)
EPS (Diluted)4.92(156.00)(96.00)(52.98)(60.00)
Weighted Avg Shares139.34K224.9K255.17K598.65K619.19K
Weighted Avg Shares (Diluted)177.53K259.16K255.17K598.65K619.19K

Trinity Biotech plc

NASDAQ:TRIB

Intrinsic Alpha fair value

Locked

Current Price

$5.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.